English
Español
Next-Generation Molecular Nutrition.
Engineered for Performance.
Global Leader in Premium GRAS-Certified Immunoceuticals. Exclusive Global Contract Manufacturing & Commercialization Platform for the PLPC-NX™ Portfolio.
Aphelar-io™ (ISRP™) | First-in-Class Immuno-Structural Reconstruction Platform for Advanced Cancer Treatment – Dubai Investment
Veridian Dubai presents Aphelar-io™ (ISRP™), the world’s first Immuno-Structural Reconstruction Platform designed as complementary support in advanced cancer treatment. Zero serious adverse events in over 24,000 applications, ambient stability, and universal compatibility with any oncology protocol. A scalable, low-risk, first-in-class investment opportunity in precision oncology.
Aphelar-io™ (ISRP™) | Immuno-Structural Reconstruction Platform – Next-Generation Support for Cancer Treatment | Panama Investment Gateway
Axerium Panama offers strategic access to Aphelar-io™ (ISRP™), the pioneering Immuno-Structural Reconstruction Platform for advanced cancer treatment. A non-pharmacological, first-in-class solution with exceptional safety (24,000+ applications, 0 % serious adverse events) and full compatibility with existing oncology therapies. High-potential investment opportunity in Latin America.
Aphelar-io™ (ISRP™) | World’s First Immuno-Structural Reconstruction Platform for Oncology and Cancer Treatment – OGRD Biotech
OGRD Biotech introduces Aphelar-io™ (ISRP™), the global first Immuno-Structural Reconstruction Platform developed as advanced structural support in cancer treatment. First-in-class, non-pharmacological mechanism with unmatched safety, ambient stability, and compatibility across all oncology protocols. A scalable and defensible investment in the future of oncology.
Corporate & Operational Snapshot
A seamless global ecosystem driven by advanced molecular synergy.
Corporate Structure
Fully licensed Panamanian corporation operating as the exclusive global manufacturing & commercialization partner within the PLPC™ Ecosystem.
Formulation Advantage
100% fat-soluble actives with precise molecular synergy and clinically relevant potency. Superior bioavailability compared to conventional supplements.
Regulatory Alignment
GRAS-certified, NAM-aligned, with full supply-chain traceability powered by proprietary STIP™ technology framework.
Intellectual Capital & Product Portfolio
Swiss Vitalabs is the exclusive global vehicle for four proprietary variants of the PLPC-NX™ immunoceutical line. Developed under the PLPC™ Platform, each 100% fat-soluble formulation is designed to activate critical cellular longevity and resilience mechanisms.
Targeted Biological Pathways
- Nrf2/KEAP1-ARE: Redox balance and endogenous antioxidant response.
- NF-κB Modulation: Controlled downregulation of pro-inflammatory transcription.
- SIRT1/PGC-1α Axis: Mitochondrial biogenesis and energy efficiency.
- LC3/ATG5 & PINK1/Parkin: Enhancement of autophagy and mitophagy (cellular cleaning).
- STING/IRF3 Pathway: Balanced innate immune surveillance without hyperactivation.
Scientific Superiority vs. Market (April 2026)
The PLPC-NX™ formulas represent a clear leap forward in the gummy category, delivering sophisticated pathway-level activity in a convenient format.
| Aspect | Market Average Gummies | Swiss Vitalabs PLPC-NX™ | Superiority Level |
|---|---|---|---|
| Active concentration | Low to moderate | High therapeutic range | Significantly higher |
| Molecular targeting | Generalist wellness claims | Specific, evidence-based pathways | Highly superior |
| Synergy | Low (random ingredient blends) | High (designed around shared cellular hubs) | Very high |
| Daily servings | 2–4 gummies | Only 1 gummy | Superior adherence |
| Innovation level | Low–Medium | Advanced molecular precision | Pioneer position |
Global Maquila & Commercialization Strategy
Executing contract manufacturing agreements across multiple jurisdictions to ensure rapid, compliant market entry.
- Asset-Light: A capital-light model preserving the PLPC™ Platform philosophy.
- Local GMP: Cost-efficient production meeting strict global standards.
- Target Markets: Mexico, Brazil, Panama, USA, UAE, and Selected GCC / Latam Regions.
- High-Margin: Enables near-term revenue generation for our manufacturing partners.
Ready to Proceed?
Secure your position as a strategic manufacturing partner or accredited investor. Why choose Swiss Vitalabs? Exclusive rights, multi-jurisdictional network, and alignment within the broader PLPC™ Platform governance framework.
Access the Full Institutional Package
- Private Placement Memorandum
- Scientific Mechanism Dossier
- Global Maquila Framework
- Legal Opinion Letters
- Complete Data Room
Contact Investor & Partnership Relations